Home » USA Broker Ratings » Exact Sciences Corporation – Consenus Indicates Potential 52.3% Upside

Exact Sciences Corporation – Consenus Indicates Potential 52.3% Upside

Exact Sciences Corporation found using ticker (EXAS) now have 12 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 135 and 105 calculating the mean target price we have 125.17. Given that the stocks previous close was at 82.16 this is indicating there is a potential upside of 52.3%. There is a 50 day moving average of 88.36 and the 200 day moving average is 104.67. The market cap for the company is $12,338m. Visit the company website at: http://www.exactsciences.com

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.